Anguillulose disséminée avec parasitémie chez un patient sous corticothérapie

Pinatelle, P.; Monbrison, Frédérique de; Bedock, B.

doi:10.1016/j.medmal.2008.11.005

Cited by 5 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L'anguillulose intestinale est Pauci- ou asymptomatique chez le sujet immunocompétent. Elle peut être mortelle en cas d'immunodépression notamment au cours d′une corticothérapie, d'une infection par le VIH ou au cours des maladies auto-immunes [ 1 ]. L'anguillulose maligne regroupe deux formes graves: l'anguillulose d'hyperinfestation et l'anguillulose disséminée.…”

Section: Discussionunclassified

“…L'atteinte pulmonaire peut se manifester par une détresse respiratoire aigue, des pneumonies alvéolaires ou interstielles souvent hémorragiques [ 2 ]. L'anguillulose disséminée se caractérise par une défaillance multiviscérale et des septicémies à germes Gram négatifs secondaire au rôle vecteur des parasites [ 1 ]. Le traitement de première intention est l'Ivermectine à la dose de 200µg/kg pendant une durée d'au moins trois jours associé à la prise en charge des défaillances viscérales [ 3 ].…”

Section: Discussionunclassified

See 1 more Smart Citation

Anguillulose maligne d’évolution fatale au cours d’un pemphigus végétant

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Anguillulose maligne d’évolution fatale au cours d’un pemphigus végétant

et al. 2015

View full text Add to dashboard Cite

show abstract

“…16,24 The second hypothesis is that the parasites benefit from the suppression of the innate and adaptive immune responses of patients undergoing treatments with immunosuppressive drugs, contributing to their reproduction, invasion, and dissemination. 25,26 the scenario of the SARS-CoV-2 pandemic, several therapies have been used with the aim of reducing or avoiding diffuse lung damage, including the use of glucocorticoids, which have the function of modulating the extent of the impacts caused by inflammation and, by extension, consequently, prevent progression to a worse clinical prognosis. Among the drugs adopted from this class is the glucocorticoid dexamethasone, which has shown positive results when used in patients undergoing invasive mechanical ventilation or just oxygen.…”

Section: Association Between Strongyloides and Glucocorticoidsmentioning

confidence: 99%

Disseminated Strongyloidiasis in Patients Diagnosed With Covid-19 Treated With Corticoids

Ticotosti,

Clemente,

Durigan

et al. 2023

J App Pharm Sci Res

View full text Add to dashboard Cite

The arrival of a new epidemic at the end of 2019 occurred with an outbreak of new cases of people with a clinical picture that ranged from a common cold to serious complications, which included severe acute respiratory syndrome (SARS). With the rapid increase in the number of infected cases, new therapeutic strategies were devised. Among them, the use of corticosteroids is highlighted as a potential reducer of the inflammatory processes caused by the disease, particularly its effect on respiration, which proved to be an important part of the pathogenesis of the disease. The use of glucocorticoids in the treatment of COVID-19, while being efficient, presents problems such as the development of severe strongyloidiasis, especially in those patients who live or have lived in endemic areas for the parasitosis, and thus screening for this condition before therapy is the best immunosuppressive procedure. The evolution to disseminated strongyloidiasis or to hyperinfection in patients co-infected with SARS-CoV-2 undergoing treatment with glucocorticoids increases in chronic, asymptomatic carriers without a previous diagnosis of Strongyloides stercoralis, and this is due to the corticosteroid stimulus of the parasite larvae. Corticosteroids are an important risk factor for the development of S. stercoralis hyperinfection, which apparently does not depend on the dosage used or duration of treatment. After diagnostic confirmation or after establishing the risk through epidemiological stratification, these patients can be submitted to prophylactic treatment with ivermectin. Therefore, as many patients with COVID-19 are undergoing glucocorticoid therapy and these medications increase the risk of developing strongyloidiasis (disseminated form and form of hyperinfection), especially in risk patients, this study was carried out in the context of this approach theme of the coexistence of this parasitological infection and viral infection by SARS-CoV-2 in patients using the aforementioned immunosuppressive therapy. This is a literature review based on the main data platforms, through which 36 articles published between the years 2020 and 2022 were included for analysis.

show abstract